Argentum Veratrum
- Manufacturer
- Uriel Pharmacy Inc.
- Effective date
- 2018-05-23
- Label type
- HUMAN OTC DRUG LABEL
- Version
- 3
- Source
- legacy-cache
- Hydrated at
- 2026-08-02 00:57:30
Label at a glance#
Contacts and useful links#
Label contents#
Full prescribing information#
INDICATIONS & USAGE SECTION
Directions: FOR ORAL USE ONLY.
DOSAGE & ADMINISTRATION SECTION
Dissolve pellets under the tongue 3-4
times daily. Ages 12 and older: 10 pellets.
Ages 2-11: 5 pellets. Under age 2: Consult
a doctor.
OTC - ACTIVE INGREDIENT SECTION
Active Ingredients: Taraxacum (Dandelion) 2X, Urtica dioica (Stinging nettle) 2X, Cuprum sulf. (Copper sulfate) 4X, Magnesium sulf. (Magnesium sulfate) 4X, Apis (Honeybee) 5X, Apis regina (Queen Bee cell with larva and nutrient fluid) 5X, Pancreas (Bovine pancreas) 5X, Saccharum Sacchari (Cane sugar) 5X, Veratrum (White hellebore) 5X, Argentum met. (Silver) 6X, Phosphorus (Yellow phosphorus) 6X, Gl. Parathyreoidea (Bovine parathyroid glands) 7X, Aurum met. (Metallic gold) 9X
INACTIVE INGREDIENT SECTION
Inactive Ingredients: Sucrose, Lactose
OTC - PURPOSE SECTION
Use: Temporary relief of headache.
OTC - KEEP OUT OF REACH OF CHILDREN SECTION
KEEP OUT OF REACH OF CHILDREN.
WARNINGS SECTION
Warnings: Claims based on traditional homeopathic practice, not accepted medical evidence. Not FDA evaluated. Contains sugar. Diabetics and persons intolerant of sucrose (sugar): Consult a doctor before use. Do not use if allergic to any ingredient. Consult a doctor before use for serious conditions or if conditions worsen or persist. If pregnant or nursing, consult a doctor before use. Do not use if safety seal is broken or missing.
OTC - QUESTIONS SECTION
Questions? Call 866.642.2858
Uriel, East Troy, WI 53120
www.urielpharmacy.com
PACKAGE LABEL.PRINCIPAL DISPLAY PANEL
DailyMed Socrata Ingredients#
| Ingredient | Type | UNII | SPL version | Uploaded |
|---|---|---|---|---|
| APIS MELLIFERA | ACTIVE INGREDIENT | 7S82P3R43Z | 1 | |
| BOS TAURUS PARATHYROID GLAND | ACTIVE INGREDIENT | SMV71DDI4T | 1 | |
| CUPRIC SULFATE | ACTIVE INGREDIENT | LRX7AJ16DT | 1 | |
| GOLD | ACTIVE INGREDIENT | 79Y1949PYO | 1 | |
| MAGNESIUM SULFATE | ACTIVE INGREDIENT | DE08037SAB | 1 | |
| PHOSPHORUS | ACTIVE INGREDIENT | 27YLU75U4W | 1 | |
| SILVER | ACTIVE INGREDIENT | 3M4G523W1G | 1 | |
| SUGARCANE | ACTIVE INGREDIENT | 81H2R5AOH3 | 1 | |
| SUS SCROFA PANCREAS | ACTIVE INGREDIENT | 9Y3J3362RY | 1 | |
| TARAXACUM PALUSTRE ROOT | ACTIVE INGREDIENT | GCZ4W7077C | 1 | |
| URTICA DIOICA | ACTIVE INGREDIENT | 710FLW4U46 | 1 | |
| VERATRUM ALBUM ROOT | ACTIVE INGREDIENT | QNS6W5US1Z | 1 | |
| APIS MELLIFERA | ACTIVE MOIETY | 7S82P3R43Z | 1 | |
| BOS TAURUS PARATHYROID GLAND | ACTIVE MOIETY | SMV71DDI4T | 1 | |
| CUPRIC CATION | ACTIVE MOIETY | 8CBV67279L | 1 | |
| GOLD | ACTIVE MOIETY | 79Y1949PYO | 1 | |
| MAGNESIUM CATION | ACTIVE MOIETY | T6V3LHY838 | 1 | |
| PHOSPHORUS | ACTIVE MOIETY | 27YLU75U4W | 1 | |
| SILVER | ACTIVE MOIETY | 3M4G523W1G | 1 | |
| SUGARCANE | ACTIVE MOIETY | 81H2R5AOH3 | 1 | |
| SUS SCROFA PANCREAS | ACTIVE MOIETY | 9Y3J3362RY | 1 | |
| TARAXACUM PALUSTRE ROOT | ACTIVE MOIETY | GCZ4W7077C | 1 | |
| URTICA DIOICA | ACTIVE MOIETY | 710FLW4U46 | 1 | |
| VERATRUM ALBUM ROOT | ACTIVE MOIETY | QNS6W5US1Z | 1 | |
| LACTOSE | INACTIVE INGREDIENT | J2B2A4N98G | 1 | |
| SUCROSE | INACTIVE INGREDIENT | C151H8M554 | 1 |
Products#
Every source-derived product name is available through these pages.
- Argentum Veratrum
- SUCROSE
- LACTOSE
- TARAXACUM PALUSTRE ROOT
- URTICA DIOICA
- CUPRIC SULFATE
- CUPRIC CATION
- MAGNESIUM SULFATE, UNSPECIFIED FORM
- MAGNESIUM CATION
- APIS MELLIFERA
- SUS SCROFA PANCREAS
- SUGARCANE
- VERATRUM ALBUM ROOT
- SILVER
- PHOSPHORUS
- BOS TAURUS PARATHYROID GLAND
- GOLD
NDC Codes#
| Product NDC | Package NDC |
|---|---|
| 48951-1101 | 48951-1101-2 |
Ingredients#
Every source-derived ingredient row is available through these pages.
| Name | UNII | Kind |
|---|---|---|
| SUCROSE | C151H8M554 | IACT |
| LACTOSE | J2B2A4N98G | IACT |
| TARAXACUM PALUSTRE ROOT | GCZ4W7077C | ACTIB |
| URTICA DIOICA | 710FLW4U46 | ACTIB |
| CUPRIC SULFATE | LRX7AJ16DT | ACTIM |
| MAGNESIUM SULFATE, UNSPECIFIED FORM | DE08037SAB | ACTIB |
| APIS MELLIFERA | 7S82P3R43Z | ACTIB |
| SUS SCROFA PANCREAS | 9Y3J3362RY | ACTIB |
| SUGARCANE | 81H2R5AOH3 | ACTIB |
| VERATRUM ALBUM ROOT | QNS6W5US1Z | ACTIB |
| SILVER | 3M4G523W1G | ACTIB |
| PHOSPHORUS | 27YLU75U4W | ACTIB |
| BOS TAURUS PARATHYROID GLAND | SMV71DDI4T | ACTIB |
| GOLD | 79Y1949PYO | ACTIB |
Source Document#
Inactive ingredient matches#
Inactive Ingredient Database values describe FDA-listed use contexts. The match method and ambiguity count are shown because ingredient names, routes, and dosage forms are not always unique. Browse recovered IID releases and source provenance.
| DailyMed ingredient | IID ingredient | UNII | Dosage form / route | Potency | Maximum daily exposure | Match |
|---|---|---|---|---|---|---|
| SUCROSE | SUCROSE | C151H8M554 | CONCENTRATE / ORAL | 4800 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | TROCHE / BUCCAL | NA | ||
| SUCROSE | SUCROSE | C151H8M554 | CAPSULE, COATED PELLETS / ORAL | 59.8 mg | ||
| LACTOSE | LACTOSE | J2B2A4N98G | CAPSULE, COATED PELLETS / ORAL | 135.2 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | WAFER / ORAL | 155.2 mg | ||
| LACTOSE | LACTOSE | J2B2A4N98G | TABLET / SUBLINGUAL | 352 mg | ||
| LACTOSE | LACTOSE | J2B2A4N98G | CONCENTRATE / ORAL | NA | ||
| LACTOSE | LACTOSE | J2B2A4N98G | TABLET, EXTENDED RELEASE / ORAL | 400 mg | ||
| LACTOSE | LACTOSE | J2B2A4N98G | INJECTION, POWDER, FOR SOLUTION / INTRAMUSCULAR | 133 mg | ||
| LACTOSE | LACTOSE | J2B2A4N98G | OINTMENT / TOPICAL | NA | ||
| LACTOSE | LACTOSE | J2B2A4N98G | INJECTION / INTRAMUSCULAR | 203.5 mg | ||
| LACTOSE | LACTOSE | J2B2A4N98G | TABLET, CHEWABLE / ORAL | 1412 mg | ||
| LACTOSE | LACTOSE | J2B2A4N98G | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION / INTRACAVITARY | 193.8 mg | ||
| LACTOSE | LACTOSE | J2B2A4N98G | CAPSULE, DELAYED RELEASE / ORAL | 231.84 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | POWDER / ORAL | 27768 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | TABLET, FILM COATED / ORAL | 145 mg | ||
| LACTOSE | LACTOSE | J2B2A4N98G | SUPPOSITORY / VAGINAL | NA | ||
| SUCROSE | SUCROSE | C151H8M554 | SUPPOSITORY / RECTAL | NA | ||
| SUCROSE | SUCROSE | C151H8M554 | PASTILLE / ORAL | 426 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | CAPSULE, DELAYED RELEASE / ORAL | 955 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | TABLET / ORAL | 4249 mg | ||
| LACTOSE | LACTOSE | J2B2A4N98G | SOLUTION / ORAL | 1682 mg/15ml | ||
| LACTOSE | LACTOSE | J2B2A4N98G | POWDER, FOR SOLUTION / ORAL | NA | ||
| SUCROSE | SUCROSE | C151H8M554 | POWDER, FOR SUSPENSION / ORAL | 40017 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | TABLET, DELAYED RELEASE / ORAL | 295.33 mg | ||
| LACTOSE | LACTOSE | J2B2A4N98G | INJECTION, SOLUTION / INTRAVENOUS | 0.45 %w/v | ||
| LACTOSE | LACTOSE | J2B2A4N98G | TABLET / BUCCAL | 296.7 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | ELIXIR / ORAL | 18000 mg | ||
| LACTOSE | LACTOSE | J2B2A4N98G | POWDER / VAGINAL | 430 mg | ||
| LACTOSE | LACTOSE | J2B2A4N98G | CAPSULE, EXTENDED RELEASE / ORAL | 120 mg | ||
| LACTOSE | LACTOSE | J2B2A4N98G | TABLET / ORAL | 2500 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION / SUBCUTANEOUS | 308 mg | ||
| LACTOSE | LACTOSE | J2B2A4N98G | INJECTION, POWDER, FOR SOLUTION / SUBCUTANEOUS | 133 mg | ||
| LACTOSE | LACTOSE | J2B2A4N98G | CAPSULE, COATED, EXTENDED RELEASE / ORAL | NA | ||
| SUCROSE | SUCROSE | C151H8M554 | CAPSULE, COATED, EXTENDED RELEASE / ORAL | 86 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | CAPSULE / ORAL | 3568 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | TABLET, COATED / ORAL | 516.42 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | DROPS / ORAL | NA | ||
| LACTOSE | LACTOSE | J2B2A4N98G | TABLET, FILM COATED, EXTENDED RELEASE / ORAL | 620 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | CAPSULE, EXTENDED RELEASE / ORAL | 619 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | SUSPENSION/ DROPS / ORAL | 3750 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | SUSPENSION, EXTENDED RELEASE / ORAL | 5400 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | LOZENGE / BUCCAL | NA | ||
| SUCROSE | SUCROSE | C151H8M554 | SUSPENSION / ORAL | 48209 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | TABLET, FILM COATED, EXTENDED RELEASE / ORAL | 119.12 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | TROCHE / ORAL | NA | ||
| SUCROSE | SUCROSE | C151H8M554 | GRANULE, FOR SUSPENSION / ORAL | 31885 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | INJECTION / INTRAVENOUS | 1950 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | TABLET / BUCCAL | 109 mg | ||
| LACTOSE | LACTOSE | J2B2A4N98G | FILM, EXTENDED RELEASE / TRANSDERMAL | 675 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | SOLUTION / ORAL | 70000 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | LIQUID / ORAL | 37500 mg | ||
| LACTOSE | LACTOSE | J2B2A4N98G | TABLET, FILM COATED / ORAL | 590 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | TABLET / SUBLINGUAL | 109 mg | ||
| LACTOSE | LACTOSE | J2B2A4N98G | SOLUTION / RECTAL | 8 %w/v | ||
| LACTOSE | LACTOSE | J2B2A4N98G | TABLET, EFFERVESCENT / ORAL | 96.5 mg | ||
| LACTOSE | LACTOSE | J2B2A4N98G | CAPSULE / ORAL | 530 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | INJECTION, SUSPENSION, EXTENDED RELEASE / SUBCUTANEOUS | 1 mg | ||
| LACTOSE | LACTOSE | J2B2A4N98G | TABLET, COATED / ORAL | 332.05 mg | ||
| LACTOSE | LACTOSE | J2B2A4N98G | CREAM / VAGINAL | 3 %w/w |
openFDA label cross-check#
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| eac53bd1-394f-ddc6-e053-2a95a90afc0e | 7e72891b-8479-4a8a-9f2c-653c1699c44a | 2022-10-11 | Warnings | 7e72891b-8479-4a8a-9f2c-653c1699c44a |
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.
